Glucagon-like peptide-1 receptor (GLP-1R)

Where the papers sit

35 papers from the last 6 months study Glucagon-like peptide-1 receptor (GLP-1R) directly · updated from PubMed 12 Oct 2026

• GLP-1R Therapeutics and Signaling

  GLP-1R drug development is moving beyond single-receptor peptides toward engineered, stapled and orally delivered ligands, including GLP-1/GIP and GLP-1/APJ agonists. Recurrent goals are stronger receptor targeting, prolonged stability, insulinotropic signaling and improved cardiovascular-kidney-metabolic outcomes. Real-world liraglutide data and outcome studies support clinical benefit in diabetes and obesity, while neuroprotective claims remain mixed. Semaglutide and tirzepatide did not slow Alzheimer disease progression in 5xFAD mice.

  12 papers · 34.3%

• Next-Generation Weight-Loss Agonists

  Weight-loss drug development is shifting toward oral, long-acting and multi-receptor GLP-1 agonists for obesity and type 2 diabetes. Phase 1–2 trials of elecoglipron, TERN-601, mazdutide and survodutide emphasize placebo-controlled weight reduction and safety, while zenagamtide targets both GLP-1 and amylin receptors. Preclinical programs add GIPR, FGF21 and prodrug strategies to widen efficacy and dosing options. The main open questions are comparative efficacy, tolerability and durability across these designs.

  11 papers · 31.4%

• GLP-1 Therapies for Fatty Liver

  GLP-1-based treatment is being extended from weight and glycemic control to MASH and MASLD, with liver injury and steatosis as key endpoints. Dual glucagon/GLP-1 agonism, including DD01, is being tested alongside dulaglutide and semaglutide. Proposed benefit is not solely weight loss: intrahepatic sinusoidal endothelial GLP-1 receptors and direct hepatoprotection recur as mechanisms. Clinical practice surveys and studies with dapagliflozin show that efficacy, cardiovascular effects and implementation remain open questions.

  5 papers · 14.3%

• Others — Pleiotropic GLP-1R Effects

  Beta-cell survival and glucose control remain central, but GLP-1R agonists are being tested across cancer, cognition, alcohol seeking and diabetic kidney responses. Liraglutide and exenatide recur, with NRF2-linked antioxidant signaling and NLRP3 modulation among reported mechanisms. Findings remain largely preclinical and model-specific. The cluster therefore points to broad pleiotropic testing rather than a single convergent therapeutic direction.

  7 papers · 20%